NUCALA 100 mg, powder for solution for injection bottle
Active ingredients: MÉPOLIZUMAB
Commercialized according to BDPMDispensing in France: Prescription only
Powder for solution for injectionbottlesous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NUCALA 100 mg, poudre pour solution injectable
- Pharmaceutical form
- poudre pour solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon(s) en verre
- Marketing authorisation holder
- GLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 16 May 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65864619CIP73003835CIP133400930038352Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MÉPOLIZUMABpoudre | 100 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.